After the publication of this work [1], it was brought to our attention that a statement in the article is not consistent with the data. The statement “Prior RBC transfusions were found to significantly increase the time to hospitalization (adjusted HR 1.373, p = 0.018) while no other covariates examined were found to impact the risk of hospitalization” is not a correct reflection of the results from the data analysis in Table 2 of the article.
The corrected statement is provided here as follows:
“Prior RBC transfusions were found to significantly shorten the time to hospitalization (adjusted HR 1.373, p = 0.018) while no other covariates examined were found to impact the risk of hospitalization.”
Contributor Information
B Douglas Smith, Email: smithdo@jhmi.edu.
Charles L Beach, Email: CLBeach@celgene.com.
Dalia Mahmoud, Email: dmahmoud@celgene.com.
Laura Weber, Email: lauraweber890@gmail.com.
Henry J Henk, Email: Henry.Henk@optum.com.
References
- Smith DB, Beach CL, Mahmoud D, Weber L, Henk HJ. Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol. 2014;3:10. doi: 10.1186/2162-3619-3-10. [DOI] [PMC free article] [PubMed] [Google Scholar]